Assembly activating protein (AAP) and its use for the manufacture of parvovirus particles essentially consisting of VP3

US9464119B2 · kind B2 · utility

Assignees

• Deutsches Krebsforschungszentrum · DE
• Medi&Gene Inc. · DE

Inventors

• Florian Sonntag · Heidelberg, DE
• Juergen Kleinschmidt · Oettingen, DE
• Markus Hoerer · Planegg, DE
• Kerstin Lux · Munich, DE

Key dates

• Filing date: Mar 4, 2010
• Grant date: Oct 11, 2016
• Expiry date: Oct 11, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14143
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3. Furthermore, the invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z. The invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use.